Clinical Trial Update: Dasatinib In Waldenström Macroglobulinemia [Phase 1]

View source ↗

Summary

Phase 1 trial of dasatinib in Waldenström macroglobulinemia was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Jorge J. Castillo, MD | Conditions: Waldenstrom Macroglobulinemia, DASATINIB | Phase 1 | Status: TERMINATED | Results posted: 2024-03-21